ID
GSK icon

Integral Derivatives’s GSK GSK Stock Holding History

Integral Derivatives’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-33,760
Closed -$1.78M – 1165
2017
Q1 		$1.78M Sell
33,760
-5,840
-15% -$296K 0.03% 341
2016
Q4 		$1.91M Buy
39,600
+34,000
+607% +$1.68M 0.04% 333
2016
Q3 		$302K Sell
5,600
-480
-8% -$26.3K 0.01% 782
2016
Q2 		$329K Sell
6,080
-1,920
-24% -$101K 0.01% 715
2016
Q1 		$405K Hold
8,000
– – 0.01% 572
2015
Q4 		$404K Buy
+8,000
New +$408K 0.01% 707
2015
Q1 		– Sell
-4,400
Closed -$235K – 1208
2014
Q4 		$235K Hold
4,400
– – ﹤0.01% 1179
2014
Q3 		$253K Buy
+4,400
New +$270K ﹤0.01% 1195

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Integral Derivatives's GSK Position: Q2 2017 in Review

Integral Derivatives sold out of GSK (GSK) in Q2 2017, closing a stake of 6,539 shares — an estimated $349K sold.

Integral Derivatives first reported a position in GSK in Q4 2013 and held it in 7 quarters. The position peaked at $1.68M in Q4 2013. 779 funds tracked by Wall St. Rank hold GSK as of Q2 2017.

  • Integral Derivatives reported no remaining GSK position as of Q2 2017 after selling out during the quarter.
  • Integral Derivatives sold 6,539 GSK shares in Q2 2017, an estimated $349K.
  • Integral Derivatives first reported a position in GSK in Q4 2013 and held it in 7 quarters.
  • Integral Derivatives's GSK position peaked at $1.68M in Q4 2013.
  • 779 funds tracked by Wall St. Rank held GSK as of Q2 2017.

Based on Integral Derivatives's 13F filing for Q2 2017, filed 14 Aug 2017.